SCHEMBL643469

SCHEMBL643469

CCC(C)OP(=O)(O)C(F)(F)C(F)(F)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40
AKR1C3 P42330 1/20 0.38
CA1 P00915 4/20 0.38
CA2 P00918 3/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
PGK1 P00558 1/20 0.37
PGK2 P07205 1/20 0.37
HSD11B1 P28845 1/20 0.37
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
RORC P51449 1/20 0.36
CA5A P35218 1/20 0.36
CA9 Q16790 1/20 0.36
GAA P10253 2/20 0.36
MGAM O43451 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL642521 0.88 ALDH1A1 (0.42) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL641569 0.86 PTPRC (0.48) AKR1C3CA1CA2CA9GAA
SCHEMBL641787 0.79 NPSR1 (0.40) ALDH1A1CES2CES1ACHEGAA
SCHEMBL5663674 0.77 ALDH1A1 (0.38) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL643449 0.76 PTPRC (0.50) AKR1C3CA1PGK1PGK2CA12
SCHEMBL10155660 0.76 ALDH1A1 (0.40) ALDH1A1POLBCA1CA2HSD11B1
SCHEMBL914891 0.75 AKR1C3 (0.44) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL643468 0.74 CA1 (0.51) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL10128365 0.73 CA1 (0.43) ALDH1A1POLBAKR1C3CA1CA2
SCHEMBL642679 0.73 TSHR (0.39) ALDH1A1PGK1PGK2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US claimed
EP-2057173-A1 AMIDES AS SPHINGOMYELINE INHIBITORS Novartis AG (CH) 2009-05-13 EP claimed
WO-2008022771-A1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2008-02-28 WO claimed
EP-2057173-B1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2014-02-26 EP disclosed
US-8119617-B2 aSMase inhibitors NOVARTIS AG (CH) 2012-02-21 US disclosed
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US disclosed
EP-2057173-A1 AMIDES AS SPHINGOMYELINE INHIBITORS Novartis AG (CH) 2009-05-13 EP disclosed
WO-2008022771-A1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022482-A1 aSMase inhibitors SMPD1, SMPD3, SMPD2 ALDH1A1 330/4885POLB 4717/4885AKR1C3 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.